Limited proteolysis of in vitro produced human androgen receptor was used to probe the different conformations of the receptor after binding of androgens and several antiandrogens. The results provide evidence for five different conformations of the receptor, as detected by the formation of proteolysis resisting fragments: 1) an initial conformation of the unoccupied receptor not resisting proteolytic attack; and receptor conformations characterized by 2) a 35-kDa proteolysis resisting fragment spanning the ligand binding domain and part of the hinge region, obtained with most antagonists, and in an initial step after agonist binding; 3) a 29-kDa proteolysis resisting fragment spanning the ligand binding domain, obtained in the presence of agonists after an activation process; 4 and 5) 30- and 25-kDa fragments, derived from 2 and 3, but missing part of the C terminus, obtained with RU486 (RU486 has antiandrogenic properties, besides its effects as an antiprogestagen/antiglucocorticoid). Concomitantly with the change from 2 to 3 (and of 4 to 5 for RU486), dissociation of the 8 S complex of receptor with associated proteins occurred. With a mutant receptor (LNCaP cell mutation in C-terminal region), some antagonists activated transcription analogous to agonists, and induced the activated receptor conformation 3. A mutant lacking the C-terminal 12 amino acids bound RU486 but not androgens, and formed with RU486 conformation 5. These data imply that, after the initial rapid binding of ligand, androgens induce a conformational change of the receptor, a process that also involves release of associated proteins. RU486 induces an inappropriate conformation of the C-terminal end, similar as found for its effect on the progesterone receptor. In contrast, the other antiandrogens act at a different step in the mechanism of action: they do not induce an abnormal conformation, but act earlier and prevent a conformation change by stabilizing a complex with associated proteins.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				M. L. Cutress, H. C. Whitaker, I. G. Mills, M. Stewart, and D. E. Neal Structural basis for the nuclear import of the human androgen receptor J. Cell Sci., April 1, 2008; 121(7): 957 - 968. [Abstract] [Full Text] [PDF]

				R. P. Pelley, K. Chinnakannu, S. Murthy, F. M. Strickland, M. Menon, Q. P. Dou, E. R. Barrack, and G. P.-V. Reddy Calmodulin-Androgen Receptor (AR) Interaction: Calcium-Dependent, Calpain-Mediated Breakdown of AR in LNCaP Prostate Cancer Cells Cancer Res., December 15, 2006; 66(24): 11754 - 11762. [Abstract] [Full Text] [PDF]

				V. Georget, W. Bourguet, S. Lumbroso, S. Makni, C. Sultan, and J.-C. Nicolas Glutamic Acid 709 Substitutions Highlight the Importance of the Interaction between Androgen Receptor Helices H3 and H12 for Androgen and Antiandrogen Actions Mol. Endocrinol., April 1, 2006; 20(4): 724 - 734. [Abstract] [Full Text] [PDF]

				J. Duff and I. J. McEwan Mutation of Histidine 874 in the Androgen Receptor Ligand-Binding Domain Leads to Promiscuous Ligand Activation and Altered p160 Coactivator Interactions Mol. Endocrinol., December 1, 2005; 19(12): 2943 - 2954. [Abstract] [Full Text] [PDF]

				T. R. Brown Nonsteroidal Selective Androgen Receptors Modulators (SARMs): Designer Androgens with Flexible Structures Provide Clinical Promise Endocrinology, December 1, 2004; 145(12): 5417 - 5419. [Full Text] [PDF]

				D. Masiello, S.-Y. Chen, Y. Xu, M. C. Verhoeven, E. Choi, A. N. Hollenberg, and S. P. Balk Recruitment of {beta}-Catenin by Wild-Type or Mutant Androgen Receptors Correlates with Ligand-Stimulated Growth of Prostate Cancer Cells Mol. Endocrinol., October 1, 2004; 18(10): 2388 - 2401. [Abstract] [Full Text] [PDF]

				Q. Wang, T. S. Udayakumar, T. S. Vasaitis, A. M. Brodie, and J. D. Fondell Mechanistic Relationship between Androgen Receptor Polyglutamine Tract Truncation and Androgen-dependent Transcriptional Hyperactivity in Prostate Cancer Cells J. Biol. Chem., April 23, 2004; 279(17): 17319 - 17328. [Abstract] [Full Text] [PDF]

				C. L. Smith and B. W. O'Malley Coregulator Function: A Key to Understanding Tissue Specificity of Selective Receptor Modulators Endocr. Rev., February 1, 2004; 25(1): 45 - 71. [Abstract] [Full Text] [PDF]

				L.-N. Song, M. Coghlan, and E. P. Gelmann Antiandrogen Effects of Mifepristone on Coactivator and Corepressor Interactions with the Androgen Receptor Mol. Endocrinol., January 1, 2004; 18(1): 70 - 85. [Abstract] [Full Text] [PDF]

				J. A. Holt, T. G. Consler, S. P. Williams, A. H. Ayscue, L. M. Leesnitzer, G. B. Wisely, and A. N. Billin Helix 1/8 Interactions Influence the Activity of Nuclear Receptor Ligand-Binding Domains Mol. Endocrinol., September 1, 2003; 17(9): 1704 - 1714. [Abstract] [Full Text] [PDF]

				E. C. Henry and T. A. Gasiewicz Agonist but Not Antagonist Ligands Induce Conformational Change in the Mouse Aryl Hydrocarbon Receptor as Detected by Partial Proteolysis Mol. Pharmacol., February 1, 2003; 63(2): 392 - 400. [Abstract] [Full Text] [PDF]

				D. Yin, Y. He, M. A. Perera, S. S. Hong, C. Marhefka, N. Stourman, L. Kirkovsky, D. D. Miller, and J. T. Dalton Key Structural Features of Nonsteroidal Ligands for Binding and Activation of the Androgen Receptor Mol. Pharmacol., January 1, 2003; 63(1): 211 - 223. [Abstract] [Full Text] [PDF]

				M. A. Rao, H. Cheng, A. N. Quayle, H. Nishitani, C. C. Nelson, and P. S. Rennie RanBPM, a Nuclear Protein That Interacts with and Regulates Transcriptional Activity of Androgen Receptor and Glucocorticoid Receptor J. Biol. Chem., December 6, 2002; 277(50): 48020 - 48027. [Abstract] [Full Text] [PDF]

				A. J. James, I. U. Agoulnik, J. M. Harris, G. Buchanan, W. D. Tilley, M. Marcelli, D. J. Lamb, and N. L. Weigel A Novel Androgen Receptor Mutant, A748T, Exhibits Hormone Concentration-Dependent Defects in Nuclear Accumulation and Activity Despite Normal Hormone-Binding Affinity Mol. Endocrinol., December 1, 2002; 16(12): 2692 - 2705. [Abstract] [Full Text] [PDF]

				T. Ueda, N. R. Mawji, N. Bruchovsky, and M. D. Sadar Ligand-independent Activation of the Androgen Receptor by Interleukin-6 and the Role of Steroid Receptor Coactivator-1 in Prostate Cancer Cells J. Biol. Chem., October 4, 2002; 277(41): 38087 - 38094. [Abstract] [Full Text] [PDF]

				T. Ueda, N. Bruchovsky, and M. D. Sadar Activation of the Androgen Receptor N-terminal Domain by Interleukin-6 via MAPK and STAT3 Signal Transduction Pathways J. Biol. Chem., February 22, 2002; 277(9): 7076 - 7085. [Abstract] [Full Text] [PDF]

				G. Buchanan, N. M. Greenberg, H. I. Scher, J. M. Harris, V. R. Marshall, and W. D. Tilley Collocation of Androgen Receptor Gene Mutations in Prostate Cancer Clin. Cancer Res., May 1, 2001; 7(5): 1273 - 1281. [Abstract] [Full Text]

				G. Buchanan, M. Yang, J. M. Harris, H. S. Nahm, G. Han, N. Moore, J. M. Bentel, R. J. Matusik, D. J. Horsfall, V. R. Marshall, et al. Mutations at the Boundary of the Hinge and Ligand Binding Domain of the Androgen Receptor Confer Increased Transactivation Function Mol. Endocrinol., January 1, 2001; 15(1): 46 - 56. [Abstract] [Full Text]

				M. Becker, E. Martin, J. Schneikert, H. F. Krug, and A. C.B. Cato Cytoplasmic Localization and the Choice of Ligand Determine Aggregate Formation by Androgen Receptor with Amplified Polyglutamine Stretch J. Cell Biol., April 17, 2000; 149(2): 255 - 262. [Abstract] [Full Text] [PDF]

				T. J. Schrader and G. M. Cooke Examination of Selected Food Additives and Organochlorine Food Contaminants for Androgenic Activity in Vitro Toxicol. Sci., February 1, 2000; 53(2): 278 - 288. [Abstract] [Full Text] [PDF]

				T. Gao, K. Brantley, E. Bolu, and M. J. McPhaul RFG (ARA70, ELE1) Interacts with the Human Androgen Receptor in a Ligand-Dependent Fashion, but Functions Only Weakly as a Coactivator in Cotransfection Assays Mol. Endocrinol., October 1, 1999; 13(10): 1645 - 1656. [Abstract] [Full Text]

				H.-C. Chang, H. Miyamoto, P. Marwah, H. Lardy, S. Yeh, K.-E. Huang, and C. Chang Suppression of Delta 5-androstenediol-induced androgen receptor transactivation by selective steroids in human prostate cancer cells PNAS, September 28, 1999; 96(20): 11173 - 11177. [Abstract] [Full Text] [PDF]

				H. Poukka, P. Aarnisalo, U. Karvonen, J. J. Palvimo, and O. A. Janne Ubc9 Interacts with the Androgen Receptor and Activates Receptor-dependent Transcription J. Biol. Chem., July 2, 1999; 274(27): 19441 - 19446. [Abstract] [Full Text] [PDF]

				S. Roux, B. Terouanne, B. Couette, M.-E. Rafestin-Oblin, and J.-C. Nicolas Conformational Change in the Human Glucocorticoid Receptor Induced by Ligand Binding Is Altered by Mutation of Isoleucine 747 by a Threonine J. Biol. Chem., April 9, 1999; 274(15): 10059 - 10065. [Abstract] [Full Text] [PDF]

				M. D. Sadar Androgen-independent Induction of Prostate-specific Antigen Gene Expression via Cross-talk between the Androgen Receptor and Protein Kinase A Signal Transduction Pathways J. Biol. Chem., March 19, 1999; 274(12): 7777 - 7783. [Abstract] [Full Text] [PDF]

				P. Alen, F. Claessens, E. Schoenmakers, J. V. Swinnen, G. Verhoeven, W. Rombauts, and B. Peeters Interaction of the Putative Androgen Receptor-Specific Coactivator ARA70/ELE1{alpha} with Multiple Steroid Receptors and Identification of an Internally Deleted ELE1{beta} Isoform Mol. Endocrinol., January 1, 1999; 13(1): 117 - 128. [Abstract] [Full Text]

				H. Miyamoto, S. Yeh, H. Lardy, E. Messing, and C. Chang Delta 5-Androstenediol is a natural hormone with androgenic activity in human prostate cancer cells PNAS, September 15, 1998; 95(19): 11083 - 11088. [Abstract] [Full Text] [PDF]

				C. A. Berrevoets, P. Doesburg, K. Steketee, J. Trapman, and A. O. Brinkmann Functional Interactions of the AF-2 Activation Domain Core Region of the Human Androgen Receptor with the Amino-Terminal Domain and with the Transcriptional Coactivator TIF2 (Transcriptional Intermediary Factor 2) Mol. Endocrinol., August 1, 1998; 12(8): 1172 - 1183. [Abstract] [Full Text]

				H. Miyamoto, S. Yeh, G. Wilding, and C. Chang Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells PNAS, June 23, 1998; 95(13): 7379 - 7384. [Abstract] [Full Text] [PDF]

				B. Couette, S. Jalaguier, C. Hellal-Levy, B. Lupo, J. Fagart, G. Auzou, and M.-E. Rafestin-Oblin Folding Requirements of the Ligand-Binding Domain of the Human Mineralocorticoid Receptor Mol. Endocrinol., June 1, 1998; 12(6): 855 - 863. [Abstract] [Full Text]

				T. Gao and M. J. McPhaul Functional Activities of the A and B Forms of the Human Androgen Receptor in Response to Androgen Receptor Agonists and Antagonists Mol. Endocrinol., May 1, 1998; 12(5): 654 - 663. [Abstract] [Full Text]

				N. A. T. M. Huizenga, J. W. Koper, P. de Lange, H. A. P. Pols, R. P. Stolk, H. Burger, D. E. Grobbee, A. O. Brinkmann, F. H. de Jong, and S. W. J. Lamberts A Polymorphism in the Glucocorticoid Receptor Gene May Be Associated with an Increased Sensitivity to Glucocorticoids in Vivo J. Clin. Endocrinol. Metab., January 1, 1998; 83(1): 144 - 151. [Abstract] [Full Text]

				H. T. Bruggenwirth, A. L. M. Boehmer, J. M. Lobaccaro, L. Chiche, C. Sultan, J. Trapman, and A. O. Brinkmann Substitution of Ala564 in the First Zinc Cluster of the Deoxyribonucleic Acid (DNA)-Binding Domain of the Androgen Receptor by Asp, Asn, or Leu Exerts Differential Effects on DNA Binding Endocrinology, January 1, 1998; 139(1): 103 - 110. [Abstract] [Full Text] [PDF]

				K. J. Modarress, J. Opoku, M. Xu, N. J. Sarlis, and S. S. Simons Jr. Steroid-induced Conformational Changes at Ends of the Hormone-binding Domain in the Rat Glucocorticoid Receptor Are Independent of Agonist Versus Antagonist Activity J. Biol. Chem., September 19, 1997; 272(38): 23986 - 23994. [Abstract] [Full Text] [PDF]

				P. de Lange, J. W. Koper, N. A. T. M. Huizenga, A. O. Brinkmann, F. H. de Jong, M. Karl, G. P. Chrousos, and S. W. J. Lamberts Differential Hormone-Dependent Transcriptional Activation and -Repression by Naturally Occurring Human Glucocorticoid Receptor Variants Mol. Endocrinol., July 1, 1997; 11(8): 1156 - 1164. [Abstract] [Full Text]

				M. I. Gonzalez and D. M. Robins Oct-1 Preferentially Interacts with Androgen Receptor in a DNA-dependent Manner That Facilitates Recruitment of SRC-1 J. Biol. Chem., February 23, 2001; 276(9): 6420 - 6428. [Abstract] [Full Text] [PDF]